Global Prusagliflozin Tablets Market Strategic Research Report

Scope of the Report

The global Prusagliflozin Tablets market size is predicted to grow from US$ 14.67 million in 2025 to US$ 79.97 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Prusagliptin is a novel, highly selective dipeptidyl peptidase‑4 inhibitor developed for the treatment of type 2 diabetes mellitus. It exerts its hypoglycemic effect by inhibiting DPP‑4 enzyme activity, thereby slowing the degradation of incretin hormones, enhancing glucose‑dependent insulin secretion, and suppressing glucagon release to regulate blood glucose levels in a physiological manner. With good oral bioavailability and favorable safety profile, it is administered orally as a single daily dose, either alone or in combination with other antidiabetic agents, to improve glycemic control in adult patients with type 2 diabetes.In 2025, global Prusogliptin production reached approximately 12–18 million bottles.

Prusogliptin operates within the competitive landscape of the global DPP-4 inhibitor market, where it carves out a distinct position as a novel, domestically developed therapeutic option. As a new entrant, it competes with several established agents, differentiating itself primarily through its optimized chemical structure, which confers high enzyme selectivity and a favorable pharmacokinetic profile. This positions it well for patients requiring multiple concomitant medications, as its low potential for drug-drug interactions enhances its clinical utility in complex comorbid populations. The market environment is characterized by a persistent, underlying demand driven by the rising global prevalence of type 2 diabetes, balanced against intense competition from both branded and generic alternatives, as well as the growing market share of newer drug classes like SGLT-2 inhibitors and GLP-1 receptor agonists. Despite these pressures, Prusogliptin benefits from strategic market positioning, leveraging its innovative profile and the expansion of the developer's product pipeline, including upcoming combination therapies, to secure a foothold and drive future growth within the evolving diabetes treatment ecosystem.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Prusagliflozin Tablets market?

What factors are driving Prusagliflozin Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Prusagliflozin Tablets market opportunities vary by end market size?

How does Prusagliflozin Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Prusagliflozin Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 7 Tablets Per Box
• 14 Tablets Per Box

Segment by Combination Therapy

• Combination With Metformin
• Combination With Sglt-2 Inhibitors

Segment by Sales Channels

• Hospitals
• Retail
• Online

Segment by Application

• Treatment Of Type 2 Diabetes Mellitus
• Improvement Of Glycemic Control
• Adjuvant Therapy For Diabetic Complications
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Prusagliflozin Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Treatment Of Type 2 Diabetes Mellitus, Improvement Of Glycemic Control, Adjuvant Therapy For Diabetic Complications evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact